pulmonary complications occurred: 13.5% (n=10) developed pleural effusion requiring chest drain; 9.5% (n=7) pneumonia; 4.1% (n=3) pulmonary embolus and 1.4% (n=1) sub-splenic

Abstract 530 Figure 1

Abstract 530 Figure 2

haematoma. Median overall survival was 55 months (95% CI 33.4-77.6)

Conclusion* Surgeons should anticipate diaphragmatic disease in advanced ovarian or peritoneal cancer – and regard debulking of such an important prognostic factor. Diaphragmatic procedures appear feasible, without significantly increasing peri-operative morbidity in the context of ultra-radical surgery.

534

BRCA STATUS AND PLATINUM-SENSITIVITY IN ADVANCED OVARIAN CANCER: A PATHOLOGICAL EVALUATION AFTER NEOADJUVANT CHEMOTHERAPY

¹R Ergasti*, ¹R Tudisco, ¹C Marchetti, ²A Iervolino, ^{1,2}A Fagotti, ^{1,2}G Scambia. ¹Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Department of Woman, Child, and Public Health, Rome, Italy; ²Catholic University of Sacred Heart, Rome, Italy

10.1136/ijgc-2021-ESGO.421

Introduction/Background* To investigate the association between the presence of BRCA1/2 mutations and the chemotherapy response score (CRS) in patients with advanced stage high-grade serous ovarian cancer (HGSOC) undergoing neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS).

Methodology We retrospectively collected patients with unresectable HGSOC, who were assessed for BRCA1/2 mutational status and underwent 3 or 4 cycles of NACT, in our Institution from 2016 to 2020. All patients received germline test on peripheral blood sampling or somatic test at diagnostic biopsy. In all patients, the omental specimen obtained at IDS was evaluated according to Bohm's CRS System.

Result(s)* Of 184 patients analyzed, 69 were BRCA1/2 mutation carriers (37.5%) and 115 were *wild type* (62.5%). In the *wild type* patients group, 80 patients had a CRS 1/2 (69.6%) and 35 patients had a CRS 3 (30.4%). In the BRCA1/2 mutation carriers group, 38 patients had a CRS 1/2 (55.1%) and 31 had a CRS 3 (44.9%), (p=0.034).

Conclusion* BRCA1/2 mutational status is significantly associated with a different response rate to chemotherapy, as assessed according to Bohm's CRS System. Whereas in BRCA1/2 mutation carriers there does not appear to be a greater predisposition to achieve a CRS 3 than a CRS 1/2, *wild type* patients appear to be more likely to have a CRS 1/2.

538

IDENTIFICATION OF MIRNA PANEL IN DIFFERENT TYPES OF ENDOMETRIOSIS AND OVARIAN CANCER

¹M Szubert*, ¹A Nowak, ¹JR Wilczynski, ²B Szymanska, ³D Domanska-Senderowska. ¹Medical University of Lodz, Poland, ¹Department of Gynecology and Obstetrics, Clinic of Surgical and Oncologic Gynecology, Lodz, Poland; ²The Central Scientific Laboratory (CoreLab) Medical University of Lodz, Lodz, Poland; ³Zaklad Biomedycyny i Genetyki, Lodz, Poland

10.1136/ijgc-2021-ESGO.422

Introduction/Background* Development of EAO (Endometriosis associated ovarian cancer) has been intensively studied in the last few years. Epigenetic regulation of genes could play an important role in this process. The objective of this study was to identify miRNAs which expression was dysregulated both in EAO and different types of endometriosis.

Methodology Material and methods: Case-control study comprised patients with ovarian endometriosis (n=47), deep infiltrating endometriosis (DIE)(n= 14), endometriosis in caesarean scar (n= 30), as well as patients with clear cell and endometrioid ovarian cancer (n= 26). For control group normal ovarian tissue from patients operated on for benign uterine pathology (n=33) and high grade ovarian cancer (HGOC) samples (n=29) were obtained. Total RNA was isolated from 1–2 tissue slices from archival formalin-fixed paraffin embedded (FFPE) blocks using the High Pure FFPE Isolation Kit (Roche). miRNA expression was first screened using Taq-Man® Human MicroRNA Array A and B (Applied Biosystems). The expression levels of 754 human miRNA genes were assessed firstly in the groups of patients with EAOC (n=10) and healthy controls (n=10). MiRNAs with altered expression profiles were then chosen for further investigations. Quantification of these selected miRNA was done using Taq-Man Advanced MicroRNA Assays (Applied Biosystems). The miRNA level was calculated as $2^{-\Delta\Delta C_t}$, while relative expression analysis of the examined gene was presented as an n-fold change in gene expression normalized to a reference gene relative to the control.

Result(s)* Several miRNAs were highly dysregulated between healthy ovarian tissue and EAOC tissue: hsa-miR-1-3p, hsa-miR-31-3p, hsa-miR-125b-1-3p, hsa-miR-200b, miR548d. Validation revealed that the level of all tested miRNAs was only slightly higher in endometrial cysts comparing to normal ovarian tissue, but significantly higher in DIE foci and all types of ovarian cancer, including HGOC. The only miRNA that were able to discriminate between EAOC and HGOC was miR-1-3p which showed high expression in EAOC and lack of expression in HGOC.

Conclusion* The same pattern of miRNA expression in DIE and EAOC, but not in endometrial cysts, could help to predict epigenetic changes that may be responsible for carcinogenesis in endometriosis foci.

inoperable group based on preoperative imaging, tumor marker levels according to our institutional protocol. In special situation where operability was not obvious, diagnostic laparoscopy was done to categorize patients. The peri-, intra-, postoperative reports and survival data was collected.

Result(s)* Complete tumor reduction was performed in 63 cases while in 49 cases only partial tumor reduction was achieved. Median progression-free survival did not differ significantly between patients who underwent primary or interval debulking surgery (PDS = 12 months, IDS = 11.2 months, $p = 0.264$). The rate of R0 resection was higher after NAC, but not significantly (37.9% vs. 54.2%, $p = 0.179$). There was no significant difference in survival of patients who successfully underwent complete tumor reduction, despite the fact that the “inoperable” group treated with NAC had a worse prognosis ($p = 0.264$). The cost-effectiveness was comparable between groups, the hospital stay and transfusion demand was favourable in neoadjuvant group.

Conclusion* The rate of optimal tumor reduction can be improved not only by increasing radicality but also by applying appropriate patient selection criteria. Neoadjuvant treatment according to the current recommendations is applicable in the inoperable group, in accordance with the protocol we use. The survival data of patients who have undergone complete tumor reduction after NAC was not inferior to those who went through primary debulking.

543

CORRELATION BETWEEN CT, INTRA-OPERATIVE ASSESSMENT AND FINAL HISTOPATHOLOGY IN DETECTING DIAPHRAGMATIC DISEASE IN ADVANCED OVARIAN CANCER. 61 CASES

¹S Addley*, ¹A Bali, ¹V Asher, ¹S Abdul, ²R Kirke, ¹A Phillips. ¹University Hospitals of Derby and Burton NHS Foundation Trust, Gynaecology Oncology; ²University Hospitals of Derby and Burton NHS Foundation Trust, Radiology

10.1136/ijgc-2021-ESGO.424

541

THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF IIIC-IVA STAGE EPITHELIAL OVARIAN CANCER – A SINGLE CENTER EXPERIENCE

S Molnár*, LÉ Vas, E Maka, R Lampé, B Vida, Z Krasznai. University of Debrecen, Department of Obstetrics and Gynecology, Debrecen, Hungary

10.1136/ijgc-2021-ESGO.423

Introduction/Background* Ovarian cancer is the 7th most common malignancy among women and the leading cause of gynecologic cancer death. The most important prognostic factor of the disease is optimal debulking surgery (R0) with no macroscopic residual disease. Achieving optimal result is a challenging duty in advanced stage (FIGO IIIC-IV). Based on previous studies neoadjuvant chemotherapy (NAC) can help to improve the optimally debulked ratio of this population with non-inferior survival outcome. The aim of our study was to evaluate the effectiveness of NAC among primarily inoperable patients. The focus was not only on survival outcome but on cost effectiveness (need for transfusion, hospitalization, ICU admission, medication demand, etc.).

Methodology Between 2015-2018 112 debulking surgeries were performed on stage FIGO IIIC-IV ovarian cancer patients. The cases were divided into potentially operable and

Introduction/Background* Whilst CT scanning is well established in the pre-operative staging of tubo-ovarian or primary peritoneal malignancy, studies suggest CT may be a poor predictor of diaphragmatic involvement.

Methodology All patients who underwent diaphragmatic surgery for stage III/V tubo-ovarian or primary peritoneal carcinoma in a cancer centre between 2008-2020 were identified. Pre-operative CT, operation notes and histopathology reports were reviewed retrospectively.

Result(s)* 61 patients were identified. In 82.0% (n=50), no diaphragmatic disease was identified on pre-operative CT. This was corroborated by negative histopathology in 6 cases – equating to 9.8% true negatives, 72.1% false negatives and negative predictive value of 12%. Of those with diaphragmatic disease identified radiologically (n=11), this was confirmed on histopathology in 10 cases – equating to 16.3% true positives, 1.6% false positives and positive predictive value of 90.9%. Our data demonstrates a sensitivity of 18.5% and specificity of 85.7% for CT in diaphragmatic assessment.

Intra-operative findings were suspicious for diaphragmatic involvement in all cases and confirmed on histopathology in 90.1% (n=55). In 6 (9.8%) patients, however, histopathology returned negative. Statistical analysis of this data was limited by the inclusion criteria – but can be interpreted as 90.2% true positives, 9.8% false positives and positive predictive